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Abstract
Metabolic associated fatty liver disease (MAFLD) is the most prevalent liver disease in
Western nations, with high heritability. A recent study of Japanese patients with the disease
suggested that TLL1 rs17047200 is associated with fibrosis; whether a similar association is
observed in Caucasian patients with MAFLD is unknown. We investigated the association
of the TLL1 rs17047200 polymorphism with liver fibrosis in a cohort of Caucasian patients
with MAFLD (n = 728). We also investigated whether TLL1 expression is altered during liver
injury in humans, in murine models of fibrosis, and in in-vitro. While TLL1 expression is upre-
gulated in the liver of humans with MAFLD and in mice, the rs17047200 variant was not
associated with fibrosis or any other histological features, or with hepatic TLL1 expression.
In conclusion, the TLL1 rs17047200 variant is not a risk variant for fibrosis in Caucasian
patients with MAFLD. However, TLL1 could be involved in the pathogenesis of liver fibrosis.
Introduction
To more accurately reflect disease the pathophysiology of fatty liver disease associated with
metabolic dysfunction, the term non-alcoholic fatty liver disease (NAFLD) has recently been
updated to metabolic (dysfunction)-associated fatty liver disease (MAFLD) [1–9]. MAFLD is a
leading cause of end-stage liver disease, hepatocellular carcinoma (HCC) and liver
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transplantation, affecting 20–30% of the world’s population [3,10,11]. Despite its high preva-
lence, only a small proportion of patients progress to significant fibrosis, the major determi-
nant of all-cause and liver-related mortality [12,13]. Thus, similar to other common diseases,
MAFLD is a complex trait in which disease phenotype results from the dynamic interaction of
environmental variables acting on a susceptible polygenic host background [14,15].
The heritable component of hepatic fibrosis has been estimated at ~50% based on a pro-
spective twin study [16]. To date, the known risk polymorphisms explain only a small fraction
of this heritability [14,17]. Thus, other as yet unidentified genetic and epigenetic variations
likely exist that contribute to fibrosis risk. Notably, we and others have demonstrated that the
fibrosis process shares common pathways across different liver diseases, but also has disease
specific signals [18–24].
A recent genome-wide study in Japanese patients with chronic hepatitis C identified the
TLL1 rs17047200 single nucleotide polymorphism (or other intronic variants in strong LD), as
a novel risk variant for HCC, indirectly via regulating liver fibrosis [25]. Consistently, we dem-
onstrated in a large cohort of patients with chronic hepatitis C that rs17047200 is associated
with fibrosis progression, but not fibrosis stage [26]. A recent study of 258 Japanese patients
with biopsy-proven MAFLD has suggested that TLL1 rs17047200 is associated with fibrosis
[27].
To increase our knowledge of shared genetic determinants influencing MAFLD and
MAFLD-related fibrosis, we determined whether the rs17047200 polymorphism influences
histological damage (fibrosis as the main objective) in a cohort of Caucasian patients
(n = 728). We also investigated whether TLL1 expression is regulated during fibrosis in
humans, in murine models of fibrosis, and in-vitro.
Methods
Patient cohort
The study comprised 728 European decent patients with biopsy-proven MAFLD, recruited
from the participating centres between 2000–2015. Subjects with secondary causes of steatosis
or alternative diagnoses were excluded, including alcohol abuse (men >30 g/day; women >20
g/day), total parenteral nutrition, chronic viral hepatitis (hepatitis B and hepatitis C), autoim-
mune liver disease, hereditary hemochromatosis, α1-antitrypsin deficiency, Wilson’s disease
and drug-induced liver injury.
Ethics approval was obtained from the Human Research Ethics Committees of the Western
Sydney Local Health District and the University of Sydney. All other sites had ethics approval
from their respective ethics committees. Written informed consent for genetic testing was
obtained from all participants.
Clinical and laboratory assessment
Demographic and clinical data were obtained including age, gender, ethnicity, height and
weight. Body mass index (BMI) was calculated as weight divided by the square of the height
(kg/m2). Diabetes was defined as fasting blood glucose� 7.0 mmol/L, previous diagnosis of
diabetes or the use of antidiabetic drugs. The homeostasis model assessment (HOMA-IR) was
calculated as: (fasting serum insulin [μU/mL] × fasting serum glucose [mmol/L])/22.5 [28]. At
the time of liver biopsy, a fasting blood sample was obtained and routine biochemical tests
were performed. Additional blood samples were drawn and frozen at −80˚C for future
research.
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Genotyping
Genotyping for TLL1 rs17047200 was undertaken using the TaqMan SNP genotyping allelic
discrimination method (Applied Biosystems, Foster City, CA, USA). All genotyping was
blinded to clinical variables.
Liver histopathology
Liver biopsies were scored by an expert liver pathologist in each participating centre unaware
of the clinical or genetic data. Histological scoring was based on the system proposed by Klei-
ner et al.29 Steatosis was graded from 0 to 3, lobular inflammation from 0 to 3 and hepatocellu-
lar ballooning from 0 to 2. Fibrosis was staged from 0 to 4 with 4 representing cirrhosis. The
steatohepatitis activity score (NAS) was calculated to quantify disease activity [29]. The inter-
observer agreement between pathologists was studied previously and was excellent for steatosis
(κ = 0.85) and good for fibrosis (κ = 0.78) [30].
TLL1 gene expression in human tissues, human primary hepatic cells and
human MAFLD
Real-time quantitative polymerase chain reaction was used to assess TLL1 mRNA expression
in a selection of 18 human tissues using TissueScan Human Normal cDNA Array (Origene,
Rockville, MD). TLL1 mRNA levels were assessed in human primary hepatocytes, primary
human hepatic stellate cells and primary human hepatic sinusoidal endothelial cells (Science-
Cell, Carlsbad, CA) and in available tissue samples from patients with steatohepatitis (n = 24).
Control samples were from patients undergoing resection for benign liver tumours in whom
all causes of liver disease were excluded (n = 27). Steatohepatitis was diagnosed using standard
histological criteria, as follows29: samples with a steatohepatitis activity score (NAS) of� 5 or a
NAS of 3–4 but with fibrosis. mRNA expression levels were determined using TaqMan probes
and master mix (Life Technologies) according to the manufacturer’s protocol. Gene expres-
sion levels were normalized for GAPDH.
Animal experimental protocol
Three different models of fibrosis were employed as generated by SMC Laboratories, Inc.
(Japan). Five mice from each fibrosis model and five mice from each control group were
included in this study. For carbon tetrachloride (CCl4)-induced fibrosis, male C57BL/6 mice
were injected intraperitoneally with CCl4 (100 μl of 5% CCl4 in mineral oil/twice weekly) for 4
weeks to induce liver fibrosis. Control mice received an equivalent volume of mineral oil. Bile
duct ligation or sham ligation was for two weeks. Experimental fibrosing steatohepatitis was
induced by administration of a methionine and choline-deficient diet (MCD diet) or a control
diet supplemented with methionine and choline for 8 weeks.
SMC Laboratories animal welfare standard operating procedures (SOPs)
The animals were maintained in a SPF facility under controlled conditions of temperature
(23 ± 2˚C), humidity (45 ± 10%), lighting (12-hour artificial light and dark cycles; light from
8:00 to 20:00) and air exchange. The animals were housed in TPX cages that were appropriate
in size for the number of mice (according to the recommendations set in the Guide for the
Care and Use of Laboratory Animals (8th Ed) _ILAR). Sterilized paper bedding and nesting
material were used and replaced once a week. Sterilized solid diet was placed in a metal lid on
the top of the cage. Pure water was provided from a water bottle equipped with a rubber stop-
per and a sipper tube. Water bottles were replaced once a week, cleaned, and sterilized in an
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autoclave and reused. If animals showed clinical signs of morbidity such as prone position, the
animal was euthanized by under excess isoflurane. The viability, clinical signs (e.g., lethargy,
twitching, labored breathing) and behavior were monitored daily.
Culture of human HSCs
Human HSCs (LX2) and primary human HSCs (ScienCell Research Laboratories (San Diego,
CA, USA)) were treated with TGFβ-1 (5ng/ml) for 24 hours and then evaluated for mRNA
expression.
All cell lines are regularly tested for mycoplasma contamination. Additionally, regular short
tandem repeat (STR) profiling is undertaken for authentication.
Statistical methods
Results are expressed as mean ± SD (standard deviation), median and interquartile range or
number (percentage) of patients. The Student’s t-test or non-parametric, i.e. Wilcoxon-Mann-
Whitney U-test or Kruskal-Wallis tests were used to compare quantitative data as appropriate.
χ2 and Fisher-exact tests were used for comparison of frequency data and to evaluate the rela-
tionships between groups. The Cochran–Armitage test was used for trend analysis. All tests
were two-tailed and p values <0.05 were considered significant. Genetic analyses were per-
formed assuming a dominant model of inheritance due to the low frequency of minor homo-
zygotes, as previously published [25,26].
Multiple logistic regression models were fitted to binary traits incorporating biologically
relevant covariates associated with the risk of liver fibrosis (age, gender, Body Mass Index
(BMI), presence of type 2 diabetes mellitus (T2DM), recruiting centre). Steatosis was dichoto-
mized as grade 1 or Grade 2 and 3, inflammation was dichotomized as absent/mild (A0-A1) or
moderate/severe (A2-A3) and fibrosis as absent/mild (F0-1) or significant (F2-4) or advanced
fibrosis (F0-F2) vs (F3-F4). Results are expressed as odds ratios and 95% confidence intervals
(CI). A power analysis was performed using the G�power program (http://www.gpower.hhu.
de/) [31]. This confirmed that our cohort had> 95% power to detect an effect size index of
0.2. Statistical analyses were performed using the statistical software package SPSS for Win-
dows, version 21 (SPSS, Chicago, IL) or program R.
Results
The TLL1 rs17047200 is not associated with steatosis or histological disease
severity in MAFLD
The clinical and biochemical characteristics of the cohort are summarized in Table 1 and are
representative of the general population. TLL1 rs17047200 was confirmed to be in Hardy–
Weinberg equilibrium with a minor allele frequency of 0.15, similar to that observed in other
European populations (MAF = 0.15), http://browser.1000genomes.org).
The association analysis of rs17047200 to MAFLD showed no relationship with fibrosis (p
= 0.7) using a dominant model, as previously reported (Fig 1, S1 Table). Likewise, no associa-
tion was observed when analysis was undertaken subdividing the cohort into those with mild
(F0–1) versus significant fibrosis (F2–4) (p = 0.3) or into early (F0-F2) vs advanced fibrosis
(F3-F4) (p = 0.2). The lack of association remained unaltered after adjusting for age, sex, BMI,
and ALT (OR: 1.2, 95%:0.828–1.745, p = 0.3). No associations were observed between
rs17047200 and any other histological features, including steatosis (p = 0.3), lobular inflamma-
tion (p = 0.8) or the NAS score (p = 0.2). Similarly, we found no correlation between
rs17047200 and any clinical variables (S2 Table).
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TLL1 is expressed in liver and in hepatic stellate cells
To investigate if TLL1 expression is related to fibrosis, we first examined mRNA expression of
the gene in several human tissues. TLL1 was expressed in many tissues including the liver,
though expression was low (Fig 2A). We next examined TLL1 expression in primary human
hepatocytes, human stellate cells, and hepatic sinusoidal endothelial cells. Overall, TLLI
mRNA expression levels were low in all three cell types, with highest expression in hepatic stel-
late cells (HHSC) suggesting a potential role in fibrosis (Fig 2B). Given this result, we investi-
gated the expression of TLL1 during fibrosis in in vitro and in vivo models, as well as in human
samples.
Table 1. Demographic, anthropometric and clinical characteristics of the patient cohort with MAFLD.
Variables MAFLD cohort (n = 728)
Age (yrs) 47 (37.3–56.9)
Male (%) 381 (52.3)
BMI (Kg/m2) 31 (27.2–39.9)
ALT (IU/L) 47 (25–77)
AST (IU/L) 31 (20–45)
Platelet (x109/L) 250 (201–297)
Cholesterol (mmol/L) 4.84 (4.22–5.67)
Triglycerides (mmol/L) 1.43 (1.04–2.1)
HDL-C (mmol/L) 1.25 (1.02–1.56)
LDL-C (mmol/L) 2.82 (2.3–3.53)
Blood glucose (mmol/L) 5.4 (4.9–6.2)
HOMA-IR 3.03 (1.87–4.66)
Steatosis grade 2–3 (%) 269 (37)
Lobular inflammation 2–3 (%) 195 (26)
Fibrosis Stage 2–4 (%) 229 (31.5)
Fibrosis Stage 0, 1, 2, 3, 4 (%) 241(33.1), 258(35.4), 150(20.6), 48(6.6), 31(4.3)
TLL1 rs17047200 AA, AT, TT (%) 527 (72.4), 181 (24.9), 20 (2.7)
Values are median with interquartile range or frequency and percentage. P values for Hardy-Weinberg equilibrium
were calculated by chi square test and was p = 0.3. P >0.05 indicates no deviation from Hardy-Weinberg
equilibrium.
https://doi.org/10.1371/journal.pone.0243590.t001
Fig 1. Frequencies of TLL1 genotypes according to hepatic fibrosis stage.
https://doi.org/10.1371/journal.pone.0243590.g001
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Hepatic expression of TLL1 in patients with MAFLD
To investigate the expression of TLL1 in human liver from patients with metabolic steatohepa-
titis and control subjects, we assessed 17 steatohepatitis patients, their characteristics are
depicted in S3 Table and 27 controls as described in methods. TLL1 mRNA levels were higher
in livers from patients with steatohepatitis compared to that in normal liver (Fig 3A). How-
ever, the rs17047200 allele did not influence hepatic TLL1 expression.
TLL1 mRNA expression is correlated with fibrosis in animal and in-vitro
models of hepatic fibrosis
To investigate the potential role of TLL1 in fibrosis, we measured its expression in livers from
mice subject to three models of fibrosing liver injury, namely carbon tetrachloride (CCl4)
Fig 2. TLL1 expression in human tissues and primary human hepatic cells (A) Distribution of TLL1 mRNA
expression in 18 human tissues. (B) TLL1 mRNA expression in primary human hepatic cell types. Gene expression
levels were assessed by quantitative polymerase chain reaction. The tissue or cell line with the highest CT value was
assigned a value of 1. HH, human hepatocytes; HHSEC, human hepatic sinusoidal endothelial cell; HHSC, human
hepatic stellate cell.
https://doi.org/10.1371/journal.pone.0243590.g002
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administration, bile duct ligation (BDL), and feeding a methionine-choline deficient (MCD)
diet. The latter model is more representative of fibrosis associated with steatohepatitis. As
shown in Fig 3B–3D, TLL1 expression was induced with fibrosis in all three models. In vitro,
TLL1 expression was induced after treatment with recombinant TGF-β1 of both human stel-
late cells (LX2) and primary HSCs (S1 Fig).
Overall, these data provide additional support for a potential profibrogenic role for TLL1
but this effect is unlikely to be modulated by rs17047200.
Discussion
Considering recent evidence that TLL1 rs17047200 is a novel risk variant for fibrosis progres-
sion and liver cancer in patients with chronic hepatitis C [25,26], we examined its potential
role in MAFLD. As we demonstrate, the TLL1 rs17047200 variant did not influence any histo-
logical parameter (steatosis, inflammation or fibrosis) in our large cohort of Caucasian
patients. However, TLL1 is expressed by human HSCs, is overexpressed in patients with meta-
bolic steatohepatitis, and in murine and in-vitro models of fibrosis.
A recent small study of Japanese patients with MAFLD (n = 258) has suggested that the
TLL1 rs17047200 T allele is associated with advanced liver fibrosis (p = 0.044) [27]. The reason
for our discrepant results is unclear, but might be attributed to differences in baseline charac-
teristics, the frequencies of the TLL1 genotype (MAF in our cohort was 0.15, while it was 0.10
in the Japanese cohort), variant size effects or differences in cohort size. The size effect of any
SNP may also vary across different populations. It is unlikely that our data could have arisen as
a result of a type 2 error (false-negative results) because initial power estimations demonstrated
that our cohort had> 95% power to detect an effect size index of 0.2. No power analysis was
provided in the other study [27]. In total, the findings suggest that the TLL1 rs17047200
genetic variant is either not a common genetic marker for liver fibrosis across different
Fig 3. Hepatic TLL1 expression in patients with MAFLD and control subjects, and in mice models of fibrosis. The
relative expression levels of TLL1 in liver samples obtained from non-steatotic controls (n = 27) and subjects with
metabolic steatohepatitis (n = 17) (A). qPCR analysis for TLL1 expression in liver samples from three well-established
models of fibrosis in the mouse, namely carbon tetrachloride (CCl4) administration (B), bile duct ligation (BDL) (C)
and, feeding a diet deficient in methionine and choline (MCD) (D). Gene expression was normalized to that of
GAPDH.
https://doi.org/10.1371/journal.pone.0243590.g003
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etiologies or alternatively that rs17047200 is unlikely to be the causative variant in Caucasian
patients. Further studies are thus required to clarify its true role.
We observed that TLL1 was expressed in many tissues including at a low level in whole
liver. At a cellular level, TLL1 was most highly expressed in primary hepatic stellate cells. An
intriguing finding was that hepatic TLL1 expression was higher in patients with steatohepatitis
compared to healthy controls. Consistent with our genetic results, TLL1 expression was not dif-
ferent according to rs17047200 genotype. Further, increased expression of TLL1 was observed
in three independent murine models of fibrosis, with the MCD diet model resembling human
metabolic steatohepatitis. We also demonstrated that TLL1 is induced in cultured human HSC
express in response to TGFβ stimulation. TLL1 is an astacin-like metalloprotease that shares
structural similarity to bone morphogenetic protein-1 (BMP1) and specifically processes pro-
collagen C-propeptides at the physiologically relevant site, whereas TLL2 lacks this activity [32].
This could explain why it is expressed mainly in HSCs in the liver given its role in collagen pro-
cessing. Further studies in in vivo models are needed to define the role of TLL1 in the pathogen-
esis of fibrosis in general and during the development of metabolic steatohepatitis.
The strength of our study lies in the large number of patients enrolled. However, some limi-
tations must be acknowledged, including the fact that given the cross-sectional nature of the
study we could not dissect associations with fibrosis progression. We also cannot rule out the
possibility that other variants in this or other genes in linkage disequilibrium with rs17047200
may be the functional variant. Notably, all SNPs even in weak LD with rs17047200 (LD = 0.20)
in Europeans are intronic variants.
In conclusion, we demonstrate that the TLL1 rs17047200 variant is not a risk variant for
fibrosis severity in Caucasian patients with MAFLD. However, TLL1 is likely involved in the
pathogenesis of liver fibrosis.
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S1 Fig. Gene expression levels of TLL1in a human hepatic stellate cell line (LX2) (A) and in
primary Human HSCs (B). Human HSCs (LX2) or primary human hepatic stellate cells were
treated with human recombinant TGF-β1 (5 ng/mL) or mock-treated for 24 hours. The rela-
tive levels of TLL1 mRNA were normalized to control. Three independent experiments were
carried out. Data represent mean ± SEM.
(DOCX)
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according to TLL1 rs17047200 genotype.
(DOCX)




Conceptualization: Ali Bayoumi, Ismail Jalil, Janett Fischer, Jacob George, Mohammed
Eslam.
Data curation: Ali Bayoumi, Ismail Jalil, Mayada Metwally.
PLOS ONE TLL1 and MAFLD
PLOS ONE | https://doi.org/10.1371/journal.pone.0243590 December 11, 2020 8 / 10
Formal analysis: Ali Bayoumi, Ismail Jalil, Mayada Metwally.
Funding acquisition: Jacob George, Mohammed Eslam.
Investigation: Ali Bayoumi, Ismail Jalil.
Methodology: Ali Bayoumi, Ismail Jalil, Mayada Metwally.
Resources: Leon A. Adams, Rocio Aller, Carmelo Garcı́a-Monzón, Marı́a Teresa Arias-Loste,
Luca Miele, Salvatore Petta, Antonio Craxı̀, Rocio Gallego-Durán, Thomas Berg, Liang
Qiao, Christopher Liddle, Elisabetta Bugianesi, Manuel Romero-Gomez, Jacob George,
Mohammed Eslam.
Supervision: Jacob George, Mohammed Eslam.
Validation: Ali Bayoumi, Ismail Jalil.
Writing – original draft: Ali Bayoumi, Ismail Jalil, Jacob George.
Writing – review & editing: Ali Bayoumi, Ismail Jalil, Mayada Metwally, Leon A. Adams,
Rocio Aller, Carmelo Garcı́a-Monzón, Marı́a Teresa Arias-Loste, Luca Miele, Salvatore
Petta, Antonio Craxı̀, Rocio Gallego-Durán, Janett Fischer, Thomas Berg, Liang Qiao,
Christopher Liddle, Elisabetta Bugianesi, Manuel Romero-Gomez, Mohammed Eslam.
References
1. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver
disease: An international expert consensus statement. J Hepatol 2020; 73(1): 202–9. https://doi.org/
10.1016/j.jhep.2020.03.039 PMID: 32278004
2. Eslam M, Sanyal AJ, George J. Toward more accurate nomenclature for fatty liver diseases. Gastroen-
terology 2019; 157(3): 590–3. https://doi.org/10.1053/j.gastro.2019.05.064 PMID: 31158374
3. Eslam M, Sanyal AJ, George J. MAFLD: A consensus-driven proposed nomenclature for metabolic
associated fatty liver disease. Gastroenterology 2020. https://doi.org/10.1053/j.gastro.2019.11.312
PMID: 32044314
4. Eslam M, Sarin SK, Wong VW-S, et al. The Asian Pacific Association for the Study of the Liver clinical
practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.
Hepatology International 2020: 1–31. https://doi.org/10.1007/s12072-019-10000-5 PMID: 31754958
5. Zheng KI, Fan J-G, Shi J-P, et al. From NAFLD to MAFLD: a “redefining” moment for fatty liver disease.
CMJ 2020; 2020: 1669. https://doi.org/10.1097/CM9.0000000000000981 PMID: 32701591
6. Shiha G, Korenjak M, Eskridge W, et al. Redefining fatty liver disease: an international patient perspec-
tive. The Lancet Gastroenterology & Hepatology 2020. https://doi.org/10.1016/S2468-1253(20)30294-
6 PMID: 33031758
7. Fouad Y, Waked I, Bollipo S, Gomaa A, Ajlouni Y, Attia D. What’s in a name? Renaming ‘NAFLD’to
‘MAFLD’. Liver International 2020.
8. Shiha GAK, Al Khatry M, et al. Nomenclature and definition of metabolic associated fatty liver disease:
a consensus from the Middle East and north Africa. Lancet Gastroenterol Hepatol 2020; published
online Nov 9 https://doi.org/10.1016/S2468-1253(20)30213-2 PMID: 33181119
9. Mendez-Sanchez N. The Latin American Association for the Study of the Liver (ALEH) position state-
ment on the redefinition of fatty liver disease. Lancet Gastroenterol Hepatol 2020 Published Online
November 9, 2020 https://doiorg/101016/S2468-1253(20)30340-X.
10. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk
factors and prevention. Nat Rev Gastro Hepat 2018; 15(1): 11–20. https://doi.org/10.1038/nrgastro.
2017.109 PMID: 28930295
11. Eslam M, Newsome PN, Anstee QM, et al. A new definition for metabolic associated fatty liver disease:
an international expert consensus statement. Journal of hepatology 2020.
12. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or
cirrhosis. Nat Rev Gastroenterol Hepatol 2013; 10(6): 330–44. https://doi.org/10.1038/nrgastro.2013.
41 PMID: 23507799
PLOS ONE TLL1 and MAFLD
PLOS ONE | https://doi.org/10.1371/journal.pone.0243590 December 11, 2020 9 / 10
13. Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, et al. Fibrosis Severity as a Determinant of
Cause-specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease. Gastroenterology
2018. https://doi.org/10.1053/j.gastro.2018.04.034 PMID: 29733831
14. Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: Clinical impact. J Hepa-
tol 2017. https://doi.org/10.1016/j.jhep.2017.09.003 PMID: 29122391
15. Eslam M, George J. Genetic contributions to NAFLD: leveraging shared genetics to uncover systems
biology. Nat Rev Gastroenterol Hepatol 2019. https://doi.org/10.1038/s41575-019-0212-0 PMID:
31641249
16. Loomba R, Schork N, Chen CH, et al. Heritability of Hepatic Fibrosis and Steatosis Based on a Prospec-
tive Twin Study. Gastroenterology 2015; 149(7): 1784–93. https://doi.org/10.1053/j.gastro.2015.08.
011 PMID: 26299412
17. Karlsen TH, Lammert F, Thompson RJ. Genetics of liver disease: From pathophysiology to clinical prac-
tice. J Hepatol 2015; 62(1 Suppl): S6–S14. https://doi.org/10.1016/j.jhep.2015.02.025 PMID: 25920091
18. Eslam M, Hashem AM, Leung R, et al. Interferon-lambda rs12979860 genotype and liver fibrosis in viral
and non-viral chronic liver disease. Nat Commun 2015; 6. https://doi.org/10.1038/ncomms7422 PMID:
25740255
19. Eslam M, Mangia A, Berg T, et al. Diverse Impacts of the rs58542926 E167K Variant in TM6SF2 on
Viral and Metabolic Liver Disease Phenotypes. Hepatology 2016; 64(1): 34–46. https://doi.org/10.
1002/hep.28475 PMID: 26822232
20. Thabet K, Asimakopoulos A, Shojaei M, et al. MBOAT7 rs641738 increases risk of liver inflammation
and transition to fibrosis in chronic hepatitis C. Nat Commun 2016; 7: 12757. https://doi.org/10.1038/
ncomms12757 PMID: 27630043
21. Buch S, Stickel F, Trepo E, et al. A genome-wide association study confirms PNPLA3 and identifies
TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat Genet 2015; 47(12): 1443–8.
https://doi.org/10.1038/ng.3417 PMID: 26482880
22. Mancina RM, Dongiovanni P, Petta S, et al. The MBOAT7-TMC4 Variant rs641738 Increases Risk of
Nonalcoholic Fatty Liver Disease in Individuals of European Descent. Gastroenterology 2016; 150(5):
1219–30 e6. https://doi.org/10.1053/j.gastro.2016.01.032 PMID: 26850495
23. El Sharkawy R, Thabet K, Lampertico P, et al. A STAT4 variant increases liver fibrosis risk in Caucasian
patients with chronic hepatitis B. Aliment Pharmacol Ther 2018. https://doi.org/10.1111/apt.14866
PMID: 29963713
24. Yang J, Trepo E, Nahon P, et al. PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carci-
noma across various etiologies and severity of underlying liver diseases. Int J Cancer 2018. https://doi.
org/10.1002/ijc.31910 PMID: 30289982
25. Matsuura K, Sawai H, Ikeo K, et al. Genome-Wide Association Study Identifies TLL1 Variant Associated
With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection. Gastro-
enterology 2017; 152(6): 1383–94. https://doi.org/10.1053/j.gastro.2017.01.041 PMID: 28163062
26. John M, Metwally M, Mangia A, et al. TLL1 rs17047200 Increases the Risk of Fibrosis Progression in
Caucasian Patients With Chronic Hepatitis C. Gastroenterology 2017; 153(5): 1448–9. https://doi.org/
10.1053/j.gastro.2017.04.056 PMID: 28993163
27. Seko Y, Yamaguchi K, Mizuno N, et al. Combination of PNPLA3 and TLL1 polymorphism can predict
advanced fibrosis in Japanese patients with nonalcoholic fatty liver disease. J Gastroenterol 2018; 53
(3): 438–48. https://doi.org/10.1007/s00535-017-1372-8 PMID: 28744823
28. Chitturi S, Farrell G, Frost L, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibro-
sis: A manifestation of lipotoxicity? Hepatology 2002; 36(2): 403–9. https://doi.org/10.1053/jhep.2002.
34738 PMID: 12143049
29. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for non-
alcoholic fatty liver disease. Hepatology 2005; 41(6): 1313–21. https://doi.org/10.1002/hep.20701
PMID: 15915461
30. Kazankov K, Barrera F, Moller HJ, et al. The macrophage activation marker sCD163 is associated with
morphological disease stages in patients with non-alcoholic fatty liver disease. Liver Int 2016. https://
doi.org/10.1111/liv.13150 PMID: 27102725
31. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for
the social, behavioral, and biomedical sciences. Behav Res Methods 2007; 39(2): 175–91. https://doi.
org/10.3758/bf03193146 PMID: 17695343
32. Scott IC, Blitz IL, Pappano WN, et al. Mammalian BMP-1/Tolloid-related metalloproteinases, including
novel family member mammalian Tolloid-like 2, have differential enzymatic activities and distributions of
expression relevant to patterning and skeletogenesis. Developmental biology 1999; 213(2): 283–300.
https://doi.org/10.1006/dbio.1999.9383 PMID: 10479448
PLOS ONE TLL1 and MAFLD
PLOS ONE | https://doi.org/10.1371/journal.pone.0243590 December 11, 2020 10 / 10
